ProCE Banner Activity

A Nursing Perspective on PARP Inhibitors in Prostate Cancer

Podcast Episodes

The treatment landscape of metastatic castrate-resistant prostate cancer (mCRPC) is continually evolving. In this podcast, an advanced practice provider discusses recent evidence on PARP inhibitors for mCRPC and how they incorporate these data into clinical practice.

Topics include the role of PARP inhibitors for mCRPC with mutations in homologous recombination repair genes, testing for BRCA1/2 and other homologous recombination repair mutations, approved indications for olaparib and rucaparib, managing adverse events with approved PARP inhibitors, and a look at the future of PARP inhibition in mCRPC.


Released: June 30, 2022

Expiration: June 29, 2023

No longer available for credit.



Brenda Martone

Brenda Martone, MSN, ANP-BC, AOCNP

Nurse Practitioner
Northwestern Medicine
Chicago, Illinois


This activity is supported by educational grants from AstraZeneca; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Merck Sharp & Dohme Corp.

Provided by

ProCE Banner



Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck Sharp & Dohme Corp.

Target Audience

Oncology NPs, PAs, and nurses


Brenda Martone, MSN, ANP-BC, AOCNP, has no relevant financial relationships to disclose.



Additional Information

Program Medium

This program has been made available online.